Provided by Tiger Fintech (Singapore) Pte. Ltd.

Relay Therapeutics

2.75
+0.06002.23%
Volume:2.03M
Turnover:5.56M
Market Cap:466.19M
PE:-1.16
High:2.80
Open:2.57
Low:2.53
Close:2.69
Loading ...

BUZZ-Relay Therapeutics rises on interim data for cancer drug

Reuters
·
11 Dec 2024

Relay Therapeutics Shares up 7.5% Premarket After Co Reports Interim Data for Breast Cancer Drug

THOMSON REUTERS
·
11 Dec 2024

Relay Therapeutics reports updated interim clinical data for RLY-2608

TIPRANKS
·
11 Dec 2024

Relay Therapeutics Announces Updated Interim Data for Rly-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

THOMSON REUTERS
·
11 Dec 2024

Relay Therapeutics Inc: 39% Confirmed Orr Across All Patients & 67% in Patients With Kinase Mutations at Rp2d

THOMSON REUTERS
·
11 Dec 2024

Relay Therapeutics Inc -Data Support Planned Initiation of 2L Pivotal Study in 2025

THOMSON REUTERS
·
11 Dec 2024

Relay Therapeutics Inc: Data Support Planned Initiation of 2L Pivotal Study in 2025

THOMSON REUTERS
·
11 Dec 2024

Relay Therapeutics-New Interim Data Show 11.4-Month Median Pfs in 2L Patients With Pi3kΑ-Mutated, Hr+/Her2- Metastatic Breast Cancer at Rp2d

THOMSON REUTERS
·
11 Dec 2024

After Plunging -30.29% in 4 Weeks, Here's Why the Trend Might Reverse for Relay Therapeutics (RLAY)

Zacks
·
06 Dec 2024

Relay Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
04 Dec 2024

Relay Therapeutics price target lowered to $18 from $19 at Leerink

TIPRANKS
·
04 Dec 2024

Relay Therapeutics Inc : H.c. Wainwright Cuts Target Price to $16 From $20

THOMSON REUTERS
·
04 Dec 2024

Relay Therapeutics price target lowered to $16 from $20 at H.C. Wainwright

TIPRANKS
·
04 Dec 2024

Relay Therapeutics Inc : Leerink Partners Cuts Target Price to $18 From $19

THOMSON REUTERS
·
04 Dec 2024

Relay Therapeutics Signs Global Licensing Deal With Elevar Therapeutics for Lirafugratinib

MT Newswires Live
·
03 Dec 2024

Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in Fgfr2-Driven Cholangiocarcinoma and Other Solid Tumors

THOMSON REUTERS
·
03 Dec 2024

Relay Therapeutics Inc - FDA Recommends Nda for Fgfr2-Driven Cca Followed by Supplemental Nda

THOMSON REUTERS
·
03 Dec 2024

Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in Fgfr2-Driven Cholangiocarcinoma and Other Solid Tumors

THOMSON REUTERS
·
03 Dec 2024

Relay Therapeutics Inc - Elevar Therapeutics Granted Worldwide Rights to Develop Lirafugratinib

THOMSON REUTERS
·
03 Dec 2024

Relay Therapeutics Inc - to Receive up to $500 Million in Payments

THOMSON REUTERS
·
03 Dec 2024